Bulletin Du Cancer最新文献

{"title":"Santé sexuelle en cancérologie : regards croisés entre bénéficiaires et professionnels d’une association de patients","authors":"Agnès Douvrel ,&nbsp;Xavier Fenouil ,&nbsp;Stéphanie Testu ,&nbsp;Eva Guillot ,&nbsp;Guillaume Buiret ,&nbsp;Claire Combe","doi":"10.1016/j.bulcan.2024.11.007","DOIUrl":"10.1016/j.bulcan.2024.11.007","url":null,"abstract":"<div><div>La santé sexuelle est un aspect central du bien-être et de la qualité de vie des patients atteints de cancer. À travers deux enquêtes distinctes, l’une réalisée auprès des patients et l’autre auprès des professionnels, nous avons évalué les besoins et les pratiques liés à la santé sexuelle en cancérologie. Les résultats révèlent que l’importance accordée à la prise en compte de la vie intime et sexuelle était plutôt élevée mais que le sujet avait été abordé pour 44 % avec un professionnel et majoritairement à leur initiative. Les types d’accompagnement sollicités étaient une consultation dédiée (38 %), et des échanges avec d’autres personnes atteintes de cancer (21 %). Plus de la moitié des professionnels n’abordait pas dans sa pratique la santé sexuelle avec les bénéficiaires. Les besoins recensés étaient une formation spécifique, des temps d’échange et de partage d’expériences avec d’autres professionnels et des ressources (documentations, sites internet de référence). La formation des professionnels, et des outils adaptés semblent nécessaires pour répondre aux attentes des patients.</div></div><div><div>Sexual health is a central aspect of the well-being and quality of life of cancer patients. Through two separate surveys, one conducted among patients and the other among professionals, we assessed the needs and practices relating to sexual health in cancer care. The results showed that the importance attached to taking intimate and sexual life into account was fairly high, but that 44% of patients had discussed the subject with a professional, and the majority had done so on their own initiative. The types of support requested were a dedicated consultation (38%) and exchanges with other people with cancer (21%). More than half of the professionals did not discuss sexual health with their patients. The needs identified were specific training, time to exchange and share experiences with other professionals, and resources (documentation, reference websites). Professional training and appropriate tools seem necessary to meet patients’ expectations.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 199-207"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between HPV-16 integration status and cervical intraepithelial neoplasia and cervical cancer in patients infected with HIV","authors":"Peizhi Wang ,&nbsp;Lin Chen ,&nbsp;Huizi Xi ,&nbsp;Baojun Yang ,&nbsp;Peiyi Liang ,&nbsp;Lianhua Tang ,&nbsp;Lijie Yang ,&nbsp;Bin Long ,&nbsp;Huang Huang","doi":"10.1016/j.bulcan.2024.11.005","DOIUrl":"10.1016/j.bulcan.2024.11.005","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to explore the mechanism by which HIV infection promotes cervical cancer and precancerous lesions.</div></div><div><h3>Methods</h3><div>This was a retrospective observational study including 96 patients with high-risk HPV-16 infection who underwent cervical biopsy, cervical conization, or hysterectomy. Among them, 43 patients were diagnosed with both HIV and cervical cancer or precancerous lesions. High-risk HPV infection (HPV16+) positive samples were collected, and total RNA was extracted and amplified by fluorescence quantitative PCR. The expression of HPV E2 and E6 in cervical tissues of HIV-infected and non-HIV-infected patients with high-risk HPV was determined.</div></div><div><h3>Results</h3><div>As the degree of cervical tissue lesions increased, the proportions of integrated HPV-16 increased significantly within both HIV-negative (<em>P</em> <!-->=<!--> <!-->0.008) and HIV-positive groups (<em>P</em> <!-->=<!--> <!-->0.027). In comparison to the HIV-positive group, although the HIV-negative group had a higher proportion of free type HPV-16 infection (64.3% vs. 35.7%) and a lower proportion of integrated type infection (41.7% vs. 58.3%), the differences were not statistically significant (<em>P</em> <!-->=<!--> <!-->0.117). The lower the CD4+ T lymphocyte level, the greater the possibility of HPV-16 integrated infection.</div></div><div><h3>Conclusions</h3><div>Patients with HIV and HPV-16 infection exhibit a significantly higher rate of integrated HPV-16 infection, which is closely linked to HIV-induced immunosuppression, particularly the depletion of CD4+ T lymphocytes. This integration accelerates the progression of cervical lesions, increasing the risk of developing high-grade cervical intraepithelial neoplasia or cervical cancer. These findings underscore the need for targeted screening and therapeutic strategies in HIV-positive women to prevent HPV-related malignancies.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 157-165"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Luspatercept en première ligne dans les syndromes myélodysplasiques transfuso-dépendants de risque très faible à intermédiaire","authors":"Urbain Tauveron-Jalenques ,&nbsp;Gaspar Aspas Requena","doi":"10.1016/j.bulcan.2024.11.011","DOIUrl":"10.1016/j.bulcan.2024.11.011","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 113-114"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing the management of immune-related adverse events and survival in patients with thoracic cancer receiving immunotherapy through artificial intelligence (electronic patient-reported outcomes): The IMPATHI study","authors":"Serge Amouin ,&nbsp;Laurent Brureau ,&nbsp;Charles Parnot ,&nbsp;Hugo Picchi ,&nbsp;Audrey Le Roy ,&nbsp;Aline Barhli ,&nbsp;Marie-Anne Audisio ,&nbsp;Marie Pautas ,&nbsp;Juliette Brezun ,&nbsp;Antoine Schernberg ,&nbsp;Hélène Vanquaethem ,&nbsp;Carole Helissey","doi":"10.1016/j.bulcan.2024.11.004","DOIUrl":"10.1016/j.bulcan.2024.11.004","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;The lung cancer continues to be the primary cause of cancer-related deaths, despite significant advancements in treatment through the introduction of immunological checkpoint inhibitors (ICI). These inhibitors, initially used as monotherapy, are now employed in combined therapies, resulting in improved survival rates. The ICI function by restoring T-cell activity to target tumor cells, but may lead to undesirable immune-related adverse events (irAE), necessitating careful management.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The IMPATHI study, a prospective observational study conducted at the Begin Military Hospital, evaluated patient adherence to ePRO-based telemonitoring using the Cureety platform. The study included patients with advanced thoracic cancer receiving immunotherapy. Minors and those who did not consent to digital surveillance were excluded. Patients filled out ePRO questionnaires, and their health status was classified into four levels. The primary objective was compliance evaluation, with secondary objectives including tolerance profile and impact on survival.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The study recruited 22 patients, with a median age of 66&lt;!--&gt; &lt;!--&gt;years. Adenocarcinoma was the most common diagnosis, and 91% of patients had metastatic disease. Patient adherence to the telemonitoring platform was 83.3%, with 64% of responses indicating stable conditions. Common adverse events included asthenia, dyspnea, and joint/muscle pain. The 24-month progression-free survival rate was 79%, and the overall survival rate was 71.1%.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;The IMPATHI study demonstrates the potential of telemonitoring in the management of lung cancer patients receiving ICI therapy, with high compliance and promising survival outcomes. Telemonitoring offers significant benefits in early detection of adverse events and personalized care to patients. Future efforts should focus on expanding access to telemonitoring for all patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Le cancer du poumon reste la principale cause de décès liés au cancer, malgré des avancées significatives avec l’introduction des inhibiteurs de points de contrôle immunologiques (ICI). Initialement utilisés en monothérapie, ces inhibiteurs sont maintenant employés en thérapies combinées, améliorant les taux de survie. Les ICI rétablissent l’activité des cellules T pour cibler les cellules tumorales, mais peuvent entraîner des événements indésirables liés à l’immunité (irAE), nécessitant une gestion attentive.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Méthodes&lt;/h3&gt;&lt;div&gt;L’étude IMPATHI, une étude observationnelle prospective à l’hôpital militaire de Begin, a évalué l’adhérence des patients à la télésurveillance basée sur ePRO via la plateforme Cureety. Elle a inclus des patients atteints de cancer thoracique avancé sous immunothérapie. Les mineurs et ceux refusant la surveillance numérique ont été exclus. Les patients ont rempli des questionnair","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 149-156"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination des enfants et adolescents traités pour une leucémie aiguë, hors allogreffés : recommandations du comité leucémies de la Société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent (SFCE)","authors":"Aphaia Roussel ,&nbsp;Camille Léglise ,&nbsp;Fanny Rialland ,&nbsp;Mylène Duplan ,&nbsp;Fanny Falaque ,&nbsp;Cécile Boulanger ,&nbsp;Aude Marie Cardine ,&nbsp;Aurélia Alimi ,&nbsp;Cécile Pochon ,&nbsp;Florence Rabian ,&nbsp;Cléo Hautefeuille ,&nbsp;Alizée Corbel ,&nbsp;Chrystelle Dupraz ,&nbsp;Cyril Lervat ,&nbsp;Fanny Alby-Laurent","doi":"10.1016/j.bulcan.2024.10.013","DOIUrl":"10.1016/j.bulcan.2024.10.013","url":null,"abstract":"<div><div>Les enfants et adolescents traités ou ayant été traités pour une leucémie aiguë ont un déficit immunitaire secondaire à la chimiothérapie responsable d’un risque accru d’infections. La vaccination peut prévenir certaines de ces infections mais son efficacité n’est pas optimale pendant la chimiothérapie. À l’arrêt de la chimiothérapie, le délai de reconstitution immunitaire varie de trois mois à plus d’un an, en fonction des sous-populations lymphocytaires, de l’âge du patient et de l’intensité du traitement reçu. Même s’ils ont récupéré leurs fonctions immunitaires, les études montrent que la plupart des patients ont perdu une partie de leur protection vaccinale après la chimiothérapie et ont besoin de doses de rappels de vaccins. La plupart des praticiens s’accordent pour dire qu’il est important de vacciner ou de revacciner ces enfants mais les pratiques sont hétérogènes chez les hémato-oncologues pédiatres français. À partir d’une étude de pratiques et d’une revue récente de la littérature, ce travail a pour objectif de proposer de nouvelles recommandations françaises concernant la stratégie vaccinale à adopter chez les enfants et adolescents traités ou ayant été récemment traités pour une leucémie aiguë, hors allogreffés, en 2024. Ces recommandations incluent notamment les modalités de vaccination contre le papillomavirus et les méningocoques mais ne traitent pas de la vaccination anti-COVID-19 dont les modalités sont amenées à évoluer trop rapidement.</div></div><div><div>Children and adolescents who are being treated or have been treated for acute leukemia have a secondary immunodeficiency linked to chemotherapy, resulting in an increased risk of infections. Some of which can be prevented by vaccination but its effectiveness is not optimal during chemotherapy. Upon cessation of chemotherapy, the time required for immune reconstitution varies from three months to more than a year, depending on lymphocyte subpopulations, the patient's age, and the intensity of the treatment received. Although they may have regained their immune functions, studies show that most patients have lost part of their vaccine-induced protection post-chemotherapy and require booster doses of vaccines. Most practitioners agree on the importance of vaccinating or revaccinating these children, but practices are heterogeneous among pediatric hematologist-oncologists in France. Based on a practice study and a recent review of the literature, this work aims to propose new French recommendations for the vaccination strategy to be adopted for children and adolescents treated or recently treated for acute leukemia, excluding allogeneic transplant recipients, in 2024. These recommendations specifically include the vaccination protocols for human papillomavirus and meningococcal infections but do not address the COVID-19 vaccination, as its guidelines are subject to rapid changes.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Pages 208-224"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sommaire","authors":"","doi":"10.1016/S0007-4551(25)00005-0","DOIUrl":"10.1016/S0007-4551(25)00005-0","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 2","pages":"Page v"},"PeriodicalIF":1.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143167269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mise à jour des recommandations pour le choix des unités de sang placentaire en greffe de cellules souches hématopoïétiques (SFGM-TC)","authors":"Valérie Dubois ,&nbsp;Lucie Blandin ,&nbsp;Marion Duclaut ,&nbsp;Alix Duquesne ,&nbsp;Lionel Faivre ,&nbsp;Romain Ferru-Clement ,&nbsp;Jean Roy ,&nbsp;Alexandre Walencik ,&nbsp;Leonardo Magro ,&nbsp;Federico Garnier","doi":"10.1016/j.bulcan.2024.01.009","DOIUrl":"10.1016/j.bulcan.2024.01.009","url":null,"abstract":"<div><div>L’évolution des pratiques et l’utilisation plus limitée des unités de sang placentaire (USP) comme source de cellules dans le cadre des allogreffes de cellules souches hématopoïétiques (CSH) nous amènent à reconsidérer les recommandations établies en ateliers de 2011 et 2012, et à proposer une mise à jour intégrant les données bibliographiques récentes. Si la compatibilité HLA était jusqu’à présent établie en basse résolution pour les loci HLA-A et B, et en haute résolution pour le locus HLA-DRB1, les revues convergent aujourd’hui vers une hausse du niveau de résolution, faisant place à une compatibilité dorénavant définie en haute résolution pour l’ensemble des loci considérés, et l’inclusion du locus HLA-C, afin d’établir un niveau de compatibilité HLA sur huit allèles (loci HLA-A, B, C et DRB1). La dose de CD34+ est un facteur déterminant dans la reconstitution hématopoïétique mais elle n’est pas corrélée au contenu en cellules nucléées totales (CNT). C’est pourquoi nous recommandons de prendre en compte ces deux données lors du choix d’une USP. Les recommandations établies par notre groupe sont présentées sous forme d’un logigramme décisionnel qui prend en compte les caractéristiques de la pathologie (maligne ou non maligne), la dose de cellules et les critères de compatibilité HLA, ainsi que des critères liés aux banques dans lesquelles sont stockées les unités.</div></div><div><div>Changing practices and the limited use of cord blood units as a source of cells for allogeneic hematopoietic stem cell transplants (HSC) led us to reconsider the recommendations established in 2011 and 2012, and to propose an update incorporating recent bibliographic data. If HLA compatibility was until now established at low resolution for HLA-A and B loci, and at high resolution for HLA-DRB1, the recent papers are converging towards an increase in the level of resolution, making way for a compatibility now defined in high resolution for all the considered loci, and the inclusion of the HLA-C locus, in order to establish a level of HLA compatibility on 8 alleles (HLA-A, B, C and DRB1). The CD34+ dose is a determining factor in hematopoietic reconstitution but it is not correlated with the total nucleated cells content. This is why we recommend taking these two data into account when choosing a cord blood unit. The recommendations established by our group are presented as a flow chart taking into account the characteristics of the underlying pathology (malignant or non-malignant), the cell dose and the HLA compatibility criteria, as well as criteria linked to the banks in which units are stored.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 1","pages":"Pages S68-S77"},"PeriodicalIF":1.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consignes alimentaires pour les patients adultes et pédiatriques en sortie d’hospitalisation post-allogreffe de cellules souches hématopoïétiques (SFGM-TC)","authors":"Carole Farrugia ,&nbsp;Alexandra Lhostette ,&nbsp;Marion Brasseur ,&nbsp;Thomas Biot ,&nbsp;Hélène Calmes ,&nbsp;Caroline Dendoncker ,&nbsp;Anne Sophie Dupret ,&nbsp;Sophie Estheve ,&nbsp;Sylivie Filiol ,&nbsp;Virginie Guidi ,&nbsp;Lisa Hadrot ,&nbsp;Manon Perez ,&nbsp;Aurélie Ravinet ,&nbsp;Laure Tardieu ,&nbsp;Léonardo Magro ,&nbsp;Serge Alfandari ,&nbsp;Nicolas Simon ,&nbsp;Sarah Guenounou ,&nbsp;Jérôme Cornillon","doi":"10.1016/j.bulcan.2024.04.014","DOIUrl":"10.1016/j.bulcan.2024.04.014","url":null,"abstract":"<div><div>L’état nutritionnel des patients après greffe de moelle osseuse joue un rôle important sur le devenir. Les consignes alimentaires post-allogreffe sont donc essentielles pour assurer une alimentation de qualité tout en assurant un risque infectieux minimal. Pour les patients, elles font partie de leurs principales préoccupations à la sortie d’hospitalisation. Dans l’objectif d’harmoniser les consignes alimentaires post-allogreffe, un groupe de travail multidisciplinaire s’est constitué au sein de nombreux centres francophones réalisant des allogreffes de cellules souches hématopoïétiques. Les consignes alimentaires ont été mises à jour grâce à ce groupe de travail, par la réalisation de réunions en visioconférence, par la diffusion d’un questionnaire en ligne, la revue de la littérature et les délibérations lors des journées d’harmonisation. Ces consignes seront intégrées dans la prochaine mise à jour du carnet de suivi post-greffe adulte et pédiatrique.</div></div><div><div>The nutritional status after bone marrow transplant plays an important role in the outcome of patients. Post-allograft dietary instructions are therefore essential to ensure quality nutrition while minimizing the risk of infection. For patients, this is one of their main concerns on discharge from hospital. With the aim of harmonizing post-allograft dietary instructions, a multidisciplinary working group has been set up within a number of French centers performing hematopoietic stem cell allogenic transplantation. The dietary guidelines have been updated by this working group, through videoconference meetings, an online questionnaire, a review of the literature and deliberations at harmonization days. These instructions will be incorporated into the next update of the adult and pediatric post-transplant follow-up booklet.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 1","pages":"Pages S87-S91"},"PeriodicalIF":1.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La survie après un cancer à La Réunion","authors":"Mohamed Khettab ,&nbsp;Franck Ah-Pine ,&nbsp;Emeline Colomba ,&nbsp;Phuong Lien Tran ,&nbsp;Jean-François Delattre ,&nbsp;Luc Bauchet ,&nbsp;Emmanuel Chirpaz","doi":"10.1016/j.bulcan.2024.12.003","DOIUrl":"10.1016/j.bulcan.2024.12.003","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 1","pages":"Pages 111-112"},"PeriodicalIF":1.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Réhabilitation pré, per et post-allogreffe de cellules souches hématopoïétiques (SFGM-TC)","authors":"Virgile Pinelli ,&nbsp;Laure Christophe ,&nbsp;Nathalie Cheron ,&nbsp;Sarah Morin ,&nbsp;Lila Gilis ,&nbsp;Candy Heuze ,&nbsp;Dominique Clerc-Renaud ,&nbsp;Laurence Morotti ,&nbsp;Benoit Vilhet ,&nbsp;Sandra Bissardon ,&nbsp;Leonardo Magro","doi":"10.1016/j.bulcan.2024.05.006","DOIUrl":"10.1016/j.bulcan.2024.05.006","url":null,"abstract":"<div><div>L’allogreffe de cellules souches hématopoïétiques reste aujourd’hui le seul traitement curatif de certaines hémopathies malignes. Ce traitement peut être responsable de plusieurs effets secondaires entraînant des déficiences physiques et psychiques multiples et interdépendantes qui altèrent la qualité de vie, la participation sociale des patients, et peuvent être vécues comme un handicap parfois plusieurs années après la greffe. Depuis plusieurs années, l’intégration de parcours de réhabilitation postgreffe se démocratise et des initiatives de prise en charge pluridisciplinaires de plus en plus précoces sont étudiées. L’objectif de ces prises en charge précoces est d’améliorer l’état fonctionnel global du patient avant, pendant et après la greffe, afin de limiter l’impact du traitement, et un retour le plus rapide à une vie la plus satisfaisante possible. La littérature internationale, et les expériences mises en place sur l’ensemble du territoire francophone décrivent des pratiques hétérogènes. L’objectif de ce travail est, d’après cette littérature et ces expériences, d’émettre des recommandations homogènes de bonnes pratiques cliniques et des axes de recherches ultérieurs concernant la réhabilitation prégreffe, pergreffe, et postgreffe de cellules souches hématopoïétiques.</div></div><div><div>Allogeneic transplantation of haematopoietic stem cells is still the only curative treatment for certain haematological malignancies. This treatment can be responsible for a number of side-effects, leading to multiple and interdependent physical and psychological deficiencies that affect patients’ quality of life and social participation, and can be experienced as a handicap, sometimes for several years after the transplant. For several years now, the integration of post-transplant rehabilitation pathways has been becoming more widespread, and initiatives to provide multidisciplinary care at an increasingly early stage are being studied. The aim of this early management is to improve the patient's overall functional state before, during and after the transplant, in order to limit the impact of the treatment and ensure the quickest possible return to a life that is as satisfying as possible. The international literature and the experiments carried out throughout the French-speaking world describe heterogeneous practices. Based on this literature and experience, the aim of this study is to issue homogenous recommendations for good clinical practice and to identify areas for further research into pre-transplant, per-transplant and post-transplant rehabilitation of haematopoietic stem cells.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 1","pages":"Pages S2-S9"},"PeriodicalIF":1.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141565575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}